RxDoctor Payments Data

John Knapp, MD

Internal Medicine · Prairieville, LANPI 1669471207

Payments from drug & device makers

$12,412in general payments, 2019–2025

Across 827 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$951
  • GSK$948
  • Boehringer Ingelheim$930
  • Lilly USA, LLC$916
  • Novo Nordisk$914
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$12,367100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,412 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$58,943
Medicare patients
164
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$201,703
MounjaroTirzepatide150$199,484
JardianceEmpagliflozin116$92,678
EliquisApixaban83$75,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$71,480
TrulicityDulaglutide27$38,389
XareltoRivaroxaban36$33,493
Tresiba Flextouch U-200Insulin Degludec31$27,499
LinzessLinaclotide31$26,554
EntrestoSacubitril/Valsartan24$21,351
VascepaIcosapent Ethyl55$19,831
TrintellixVortioxetine Hydrobromide23$17,957
RybelsusSemaglutide15$17,344
SavellaMilnacipran Hcl17$14,238
MyrbetriqMirabegron18$12,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$916$237,873177 claims
Novo NordiskOzempic, Rybelsus$914$219,047181 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr$930$114,601144 claims
GSKTrelegy Ellipta, Breo Ellipta$948$78,387118 claims
PfizerEliquis$951$75,86983 claims
AbbVieLinzess, Savella, Synthroid$2,111$45,114122 claims
Johnson & JohnsonXarelto$427$33,49336 claims
NovartisEntresto$195$21,35124 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$700$17,95723 claims
Astellas Pharma US IncMyrbetriq$286$12,85718 claims
AstraZenecaSymbicort$374$4,64713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Prairieville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →